Onartuzumab联合厄洛替尼对比厄洛替尼治疗既往经治的IIIB或IV期非小细胞肺癌的III期随机试验(METLung)结果
III期METLung研究纳入499例经铂类化疗后进展的MET免疫组化阳性局部晚期或转移性非小细胞肺癌患者,随机接受Onartuzumab联合厄洛替尼或安慰剂联合厄洛替尼。Onartuzumab组中位OS为6.8个月,对照组为9.1个月(分层HR 1.27,95%CI 0.98-1.65,P=.067),未改善临床结局。
要点
- Onartuzumab联合厄洛替尼组中位OS 6.8个月,对照组9.1个月,分层HR 1.27(95%CI 0.98-1.65),未达统计学显著。
- 中位PFS分别为2.7个月与2.6个月(分层HR 0.99,95%CI 0.81-1.20,P=.92),ORR分别为8.4%与9.6%。
- 探索性分析显示MET FISH状态和基因表达亚组未见Onartuzumab获益,EGFR突变患者有OS缩短趋势(HR 4.68,95%CI 0.97-22.63)。
核心结论
- Onartuzumab联合厄洛替尼未改善MET阳性非小细胞肺癌患者的临床结局,且Onartuzumab组OS较厄洛替尼组缩短。
研究设计与样本
- III期随机试验OAM4971g(METLung),纳入499例经铂类化疗后进展的MET免疫组化阳性局部晚期或转移性非小细胞肺癌患者。
- 患者按1:1随机分配至Onartuzumab(15 mg/kg静脉注射,每21天周期第1天)联合每日口服厄洛替尼150 mg组(n=250)或静脉安慰剂联合每日口服厄洛替尼150 mg组(n=249)。
- 主要终点为意向治疗人群的总生存期(OS);次要终点包括中位无进展生存期、总缓解率、生物标志物分析和安全性。
主要发现
- Onartuzumab组 vs 安慰剂组中位OS为6.8个月 vs 9.1个月(分层HR 1.27,95%CI 0.98-1.65,P=.067),Onartuzumab组死亡人数更多(130例[52%] vs 114例[46%])。
- Onartuzumab组 vs 安慰剂组中位PFS为2.7个月 vs 2.6个月(分层HR 0.99,95%CI 0.81-1.20,P=.92)。
- Onartuzumab组 vs 安慰剂组总缓解率分别为8.4% vs 9.6%。
- 探索性分析使用MET荧光原位杂交状态和基因表达,显示Onartuzumab无获益;EGFR突变患者接受Onartuzumab治疗有OS缩短趋势(HR 4.68,95%CI 0.97-22.63)。
- 实验组 vs 对照组3-5级不良事件发生率分别为56.0% vs 51.2%,严重不良事件分别为33.9% vs 30.7%。
关键数值与推荐
- Onartuzumab组 vs 安慰剂组中位OS 6.8个月 vs 9.1个月(分层HR 1.27,95%CI 0.98-1.65,P=.067)。
- Onartuzumab组 vs 安慰剂组中位PFS 2.7个月 vs 2.6个月(分层HR 0.99,95%CI 0.81-1.20,P=.92)。
- Onartuzumab组 vs 安慰剂组总缓解率8.4% vs 9.6%。
- EGFR突变患者接受Onartuzumab治疗有OS缩短趋势(HR 4.68,95%CI 0.97-22.63)。
- 实验组 vs 对照组3-5级不良事件发生率56.0% vs 51.2%,严重不良事件33.9% vs 30.7%。
临床怎么用
- Onartuzumab联合厄洛替尼未改善MET阳性非小细胞肺癌患者的临床结局,原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The phase III OAM4971g study (METLung) examined the efficacy and safety of onartuzumab plus erlotinib in patients with locally advanced or metastatic non-small-cell lung cancer selected by MET immunohistochemistry whose disease had progressed after treatment with a platinum-based chemotherapy regimen. Patients and Methods Patients were randomly assigned at a one-to-one ratio to receive onartuzumab (15 mg/kg intravenously on day 1 of each 21-day cycle) plus daily oral erlotinib 150 mg or intravenous placebo plus daily oral erlotinib 150 mg. The primary end point was overall survival (OS) in the intent-to-treat population. Secondary end points included median progression-free survival, overall response rate, biomarker analysis, and safety. Results A total of 499 patients were enrolled (onartuzumab, n = 250; placebo, n = 249). Median OS was 6.8 versus 9.1 months for onartuzumab versus placebo (stratified hazard ratio [HR], 1.27; 95% CI, 0.98 to 1.65; P = .067), with a greater number of deaths in the onartuzumab arm (130 [52%] v 114 [46%]). Median progression-free survival was 2.7 versus 2.6 months (stratified HR, 0.99; 95% CI, 0.81 to 1.20; P = .92), and overall response rate was 8.4% and 9.6% for onartuzumab versus placebo, respectively. Exploratory analyses using MET fluorescence in situ hybridization status and gene expression showed no benefit for onartuzumab; patients with EGFR mutations showed a trend toward shorter OS with onartuzumab treatment (HR, 4.68; 95% CI, 0.97 to 22.63). Grade 3 to 5 adverse events were reported by 56.0% and 51.2% of patients, with serious AEs in 33.9% and 30.7%, for experimental versus control arms, respectively. Conclusion Onartuzumab plus erlotinib did not improve clinical outcomes, with shorter OS in the onartuzumab arm, compared with erlotinib in patients with MET-positive non-small-cell lung cancer.
引用
- Spigel DR, Edelman MJ, O'Byrne K, et al. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. J Clin Oncol. 2016. PMID: 27937096. doi:10.1200/JCO.2016.69.2160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。